Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;58(6):647-658.
doi: 10.1038/s41409-023-01943-3. Epub 2023 Mar 6.

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey

Jakob R Passweg  1 , Helen Baldomero  2 , Fabio Ciceri  3 , Selim Corbacioglu  4 , Rafael de la Cámara  5 , Harry Dolstra  6 , Bertram Glass  7 , Raffaella Greco  3 , Donal P McLornan  8 , Bénédicte Neven  9 , Régis Peffault de Latour  10 , Zinaida Perić  11 , Annalisa Ruggeri  3 , John A Snowden  12 , Anna Sureda  13
Affiliations

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey

Jakob R Passweg et al. Bone Marrow Transplant. 2023 Jun.

Abstract

In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received advanced cellular therapies, 2524 of which were CAR-T treatments, an additional 3245 received DLI. Changes compared to the previous year were CAR-T treatment (+35%), allogeneic HCT +5.4%, autologous HCT +3.9%, more pronounced in non-malignant disorders. Main indications for allogeneic HCT were myeloid malignancies 10,745 (58%), lymphoid malignancies 5127 (28%) and non-malignant disorders 2501 (13%). Main indications for autologous HCT were lymphoid malignancies 22,129 (90%) and solid tumors 1635 (7%). In allogeneic HCT, use of haploidentical donors decreased by -0.9% while use of unrelated and sibling donors increased by +4.3% and +9%. Cord blood HCT decreased by -5.8%. Pediatric HCT increased overall by +5.6% (+6.9% allogeneic and +1.6% autologous). Increase in the use of CAR-T was mainly restricted to high-income countries. The drop in HCT activity reported in 2020 partially recovered in 2021, the second year of the SARS-CoV-2 pandemic. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual EBMT report reflects current activities useful for health care resource planning.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Absolute numbers of patients treated in the years in Europe 1990 to 2021.
a Absolute numbers of patients receiving their first allogeneic or autologous HCT in Europe 1990–2021. b Absolute numbers of patients receiving donor lymphocyte infusions in Europe 1997–2021.
Fig. 2
Fig. 2. Relative proportion of disease indications for HCT in Europe 2021.
Green shades: myeloid malignancies, blue: lymphoid malignancies, brown: solid tumors and red: non-malignant disorders. a Allogeneic HCT. b Autologous HCT.
Fig. 3
Fig. 3. Difference in the percentage of numbers of allogeneic and autologous HCT by diagnosis reported between the years 2019 and 2020 (left) and between the years 2020 and 2021 (right).
a Allogeneic HCT. b Autologous HCT.
Fig. 4
Fig. 4
Change in choice of donor type in Europe from 1990 to 2021.
Fig. 5
Fig. 5. Trend in the transplant rates of HCT for five populous countries in the years 2000 to 2021.
a Allogeneic HCT (all transplants). b Allogeneic HCT for AML (first transplants). c Allogeneic HCT for ALL (first transplants). d Autologous HCT (all transplants). e Autologous HCT for NHL (first transplants). f Autologous HCT for PCD (first transplants).
Fig. 6
Fig. 6
Absolute number of patients receiving a CAR-T cellular therapy by indication in Europe 2019–2021.
Fig. 7
Fig. 7
Patient rates per 10 million population for CAR-T cellular therapies in Europe 2021.
Fig. 8
Fig. 8. Comparison of rates per 10 million population of allogeneic or autologous HCT in NHL versus CAR-T.
a Rates per 10 million population of autologous HCT for NHL versus CAR-T rates. b Rates per 10 million population of allogeneic HCT for NHL versus CAR-T rates.
See this image and copyright information in PMC

References

    1. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT) Bone Marrow Transplant. 1991;8:197–201. - PubMed
    1. Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44. doi: 10.1016/j.blre.2018.11.001. - DOI - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472. doi: 10.1056/NEJMp078166. - DOI - PubMed
    1. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39. doi: 10.1038/s41409-022-01691-w. - DOI - PMC - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed

Publication types

Substances